Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 10,300 Shares

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 10,300 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $1.01, for a total value of $10,403.00. Following the sale, the insider now directly owns 316,604 shares of the company’s stock, valued at $319,770.04. The trade was a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, December 19th, Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $48,048.10.

Nektar Therapeutics Stock Performance

Shares of NKTR traded down $0.02 during midday trading on Friday, hitting $0.93. The company had a trading volume of 1,217,794 shares, compared to its average volume of 2,430,165. The company’s 50-day simple moving average is $0.92 and its 200-day simple moving average is $1.12. The firm has a market capitalization of $171.95 million, a P/E ratio of -1.11 and a beta of 0.58. Nektar Therapeutics has a 1 year low of $0.63 and a 1 year high of $1.93.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Piper Sandler began coverage on Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $6.50 target price on shares of Nektar Therapeutics in a report on Monday, January 13th. Finally, B. Riley began coverage on Nektar Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $4.00 target price for the company. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $4.08.

Hedge Funds Weigh In On Nektar Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Two Sigma Securities LLC boosted its stake in shares of Nektar Therapeutics by 56.3% in the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 9,958 shares during the period. Harvest Investment Services LLC purchased a new position in shares of Nektar Therapeutics in the 4th quarter valued at about $27,000. US Asset Management LLC purchased a new position in shares of Nektar Therapeutics in the 4th quarter valued at about $31,000. Valence8 US LP purchased a new position in shares of Nektar Therapeutics in the 3rd quarter valued at about $34,000. Finally, Intech Investment Management LLC purchased a new position in shares of Nektar Therapeutics in the 3rd quarter valued at about $41,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.